News

This scenario emphasizes the need to gain an understanding of the role of hearing impairment in vision rehabilitation outcomes, particularly as they relate to functional independence.

The manufacturer notes that TECNIS PureSee is the first US EDOF IOL cleared by the FDA without contrast sensitivity cautions.

According to the manufacturer, TECNIS PureSee is the first US EDOF IOL approved by the FDA with no warning on contrast sensitivity.

The 3rd Winterthur Ophthalmology Symposium in Winterthur, Switzerland, on 12–13 March 2026 will feature plenary talks, hands-on workshops, satellite sessions, poster presentations, and a gala honoring the Otto Haab Medal.

The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED

According to the company, the lens is the first and only FDA-approved EDOF IOL in the US without a warning regarding loss of contrast sensitivity.

Marta Pazos, MD, PhD, on how OCT and emerging AI can help spot preperimetric glaucoma years before vision loss while avoiding false positives from myopia and disc anatomy.

Experts share practical and research-based advancements, offering actionable strategies in diagnosis, treatment, and early detection.

For Jeffry D. Gerson, OD, FAAO, an early fascination with retinal disease—sparked during residency and shaped by mentorship and emerging OCT technology—led to a career focused on education and OD-MD collaboration.

The BIM-IOL System consists of 2 non-bioerodible drug pads attached to the optic-haptic junction of a monofocal intraocular lens (IOL), which is implanted as part of routine cataract surgery.

The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

Paula Anne Newman-Casey, MD, MS, explains the multifactorial needs and her decades-long research that resulted in the SEE program for glaucoma patients.

Ophthalmologists report dry eye’s mixed mechanisms, symptom-driven diagnosis, uneven treatment response, and payer hurdles—what needs fixing next.

FDA greenlights first human trial of SVT-001, a regenerative cell therapy aiming to restore vision for patients with rare familial drusen.

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including Medicare coverage limitations, out-of-pocket costs, and the role of assistance programs such as Good Days in expanding treatment access.

Dhoot discusses the full results of the 5-year GALE extension study of pegcetacoplan in patients with GA secondary to age-related macular degeneration.

The planned phase 3 trial will evaluate the triamcinolone acetonide injectable for managing inflammation and pain after cataract surgery.

Learn how OCT aids neuro-ophthalmology, where it falls short, and why AI plus neurologist–ophthalmologist teamwork prevents misdiagnosis.

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss how retina specialists identify appropriate candidates for complement inhibitor therapy in geographic atrophy, set patient expectations, and monitor treatment in real-world clinical practice.

Cases highlight faricimab’s dual VEGF/ANG2 action for severe diabetic macular edema—faster drying, better vision, longer intervals.

The 6-month Support, Educate, Empower (SEE) program was associated with a 20% improvement in glaucoma treatment adherence and reduced distress among adult patients.

Steffen Hamann, PhD, FEBO, FRCOphth, offers insight into the landscape for optic disc drusen and the impact of advances in OCT.

Leng discusses preliminary results from an ongoing study investigating the interaction between pegcetacoplan and anti-VEGF treatments in patients with GA.

Joseph A. Anaya, MD, MBA, and Ashkan M. Abbey, MD, FASRS, FAAO, consider how emerging treatments impact patient vision, functional outcomes, and practical management of geographic atrophy.